Luca Licata: Recurrence Timing After Neoadjuvant Chemo-Immunotherapy in Early-Stage TNBC
Luca Licata, Medical Oncologist at San Raffaele Hospital, shared a post on X:
“Just out in Clinical Cancer Research our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC
We analyzed 5 major trials
Early relapse: up to 83% of all recurrences
Why this matters
Trials analyzed: KEYNOTE-522, IMpassion031, NeoTRIP, GeparNuevo, NSABP B59/GeparDouze
– Recurrence rates by 48m: 14–29%
– Of those, ~65–83% were early (< 24m from random)
– In patients with residual disease: early relapse up to 89%!
Most relapses happen fast: within 18m from randomization (DFI < 6m)
These patients are routinely excluded from trials. Urgent need to design studies targeting this high-risk group – industry and academia, take note!
Grateful to work with an amazing team: Marco Mariani, Giulia Viale, Erika Hamilton, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Christos Sotiriou, Lajos Pusztai and, of course… Giampaolo Bianchini.”
Title: Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Authors: Luca Licata, Marco Mariani, Giulia Viale, Rebecca Dent, Sara M. Tolaney, Peter Schmid, Erika Hamilton, Christos Sotiriou, Lajos Pusztai, Giampaolo Bianchini
More posts featuring Luca Licata on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023